Barclays raised the firm’s price target on Arvinas (ARVN) to $18 from $16 and keeps an Overweight rating on the shares. The firm adjusted price targets in the biotechnology space as part of its 2026 outlook.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas Reveals Promising Preclinical Data for ARV-393
- Arvinas announces preclinical data for ARV-393
- Arvinas price target raised to $15 from $14 at Stephens
- Arvinas Holding Company: Balancing Potential and Uncertainty with a Hold Rating
- Promising Pipeline Developments and Strategic Shift Justify Buy Rating for Arvinas Holding Company